MA50383B1 - Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos - Google Patents

Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Info

Publication number
MA50383B1
MA50383B1 MA50383A MA50383A MA50383B1 MA 50383 B1 MA50383 B1 MA 50383B1 MA 50383 A MA50383 A MA 50383A MA 50383 A MA50383 A MA 50383A MA 50383 B1 MA50383 B1 MA 50383B1
Authority
MA
Morocco
Prior art keywords
treatment
therapeutic agents
restless legs
legs syndrome
leucine
Prior art date
Application number
MA50383A
Other languages
English (en)
Other versions
MA50383A (fr
Inventor
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA50383A publication Critical patent/MA50383A/fr
Publication of MA50383B1 publication Critical patent/MA50383B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le traitement de maladies neurodégénératives comprenant l'administration de leucine, d'acétyl-leucine ou d'un sel pharmaceutiquement acceptable de celles-ci.
MA50383A 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos MA50383B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574137P 2017-10-18 2017-10-18
PCT/US2018/018420 WO2019078915A1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour maladies neurodégénératives
EP18708286.2A EP3697399B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Publications (2)

Publication Number Publication Date
MA50383A MA50383A (fr) 2020-08-26
MA50383B1 true MA50383B1 (fr) 2026-01-30

Family

ID=66174216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50383A MA50383B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Country Status (24)

Country Link
US (1) US11793782B2 (fr)
EP (2) EP3697399B1 (fr)
JP (1) JP2021500342A (fr)
KR (1) KR102549684B1 (fr)
CN (1) CN111542314B (fr)
AU (1) AU2018351709B2 (fr)
CA (1) CA3079194A1 (fr)
DK (1) DK3697399T3 (fr)
ES (1) ES3057584T3 (fr)
FI (1) FI3697399T3 (fr)
HR (1) HRP20251695T1 (fr)
IL (1) IL273929B2 (fr)
LT (1) LT3697399T (fr)
MA (1) MA50383B1 (fr)
MD (1) MD3697399T2 (fr)
MX (1) MX2020003427A (fr)
PL (1) PL3697399T3 (fr)
PT (1) PT3697399T (fr)
RS (1) RS67601B1 (fr)
RU (1) RU2763425C2 (fr)
SG (1) SG11202003390UA (fr)
SI (1) SI3697399T1 (fr)
SM (1) SMT202500483T1 (fr)
WO (1) WO2019078915A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CA3091353A1 (fr) * 2018-02-15 2019-08-22 Intrabio Ltd Agents therapeutiques permettant de traiter le syndrome des jambes sans repos
WO2025163129A1 (fr) * 2024-02-01 2025-08-07 Intrabio Ltd. Acétylleucine pour le traitement de la maladie de parkinson
WO2025166100A1 (fr) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions et méthodes de traitement de troubles neurodéveloppementaux

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009435A (es) * 2003-03-06 2005-11-23 Celgene Corp Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
RU2458049C2 (ru) * 2003-09-17 2012-08-10 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
KR101730290B1 (ko) * 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
EP2289886A1 (fr) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoides agonistes du facteur de croissance nerveuse et leur utilisation en tant que médicaments
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
EP2588130B1 (fr) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Administration au snc d'agents thérapeutiques
WO2015129527A1 (fr) * 2014-02-27 2015-09-03 株式会社メドレックス Timbre transdermique contenant du pramipexole pour le traitement d'une maladie neurodégénérative
DE102016000393A1 (de) 2015-10-01 2017-04-06 Linde Aktiengesellschaft Verfahren zum Verflüssigen einer Kohlenwasserstoff-reichen Fraktion
MA43828B1 (fr) * 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives

Also Published As

Publication number Publication date
DK3697399T3 (da) 2025-12-22
MA50383A (fr) 2020-08-26
RS67601B1 (sr) 2026-01-30
RU2020115710A3 (fr) 2021-11-18
BR112020007657A2 (pt) 2020-09-29
CA3079194A1 (fr) 2019-04-25
FI3697399T3 (fi) 2026-01-08
SMT202500483T1 (it) 2026-01-12
IL273929B2 (en) 2024-11-01
EP3697399A1 (fr) 2020-08-26
HRP20251695T1 (hr) 2026-02-27
ES3057584T3 (en) 2026-03-03
LT3697399T (lt) 2026-01-12
AU2018351709B2 (en) 2024-01-04
PT3697399T (pt) 2025-12-24
US11793782B2 (en) 2023-10-24
MX2020003427A (es) 2020-09-14
IL273929B1 (en) 2024-07-01
RU2020115710A (ru) 2021-11-18
AU2018351709A1 (en) 2020-05-07
US20210196659A1 (en) 2021-07-01
KR20200074170A (ko) 2020-06-24
EP4467138A3 (fr) 2025-02-26
EP3697399B1 (fr) 2025-11-26
JP2021500342A (ja) 2021-01-07
WO2019078915A1 (fr) 2019-04-25
EP4467138A2 (fr) 2024-11-27
RU2763425C2 (ru) 2021-12-29
IL273929A (en) 2020-05-31
SI3697399T1 (sl) 2026-02-27
SG11202003390UA (en) 2020-05-28
KR102549684B1 (ko) 2023-06-29
MD3697399T2 (ro) 2026-02-28
CN111542314A (zh) 2020-08-14
PL3697399T3 (pl) 2026-03-23
CN111542314B (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MX2024010140A (es) Nuevos metodos.
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
EP3490987A4 (fr) Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv.
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EP3606570B8 (fr) Compositions médicamenteuses à base de collagène peptidique pour l'utilisation dans le traitement des maladies, troubles ou blessures oculaires
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
EP3530278A4 (fr) Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA51836B1 (fr) Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
WO2017129577A8 (fr) Gabapentine ophtalmique pour le traitement d'ulcères cornéens
WO2019059868A3 (fr) Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MA39833B1 (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives